Nanoparticle conjugates of a highly potent toxin enhance safety and circumvent platinum resistance in ovarian cancer
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Nanoparticle conjugates of a highly potent toxin enhance safety and circumvent platinum resistance in ovarian cancer
Authors
Keywords
-
Journal
Nature Communications
Volume 8, Issue 1, Pages -
Publisher
Springer Nature
Online
2017-12-13
DOI
10.1038/s41467-017-02390-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Maximizing Synergistic Activity When Combining RNAi and Platinum-Based Anticancer Agents
- (2017) Haihua Xiao et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- A subset of platinum-containing chemotherapeutic agents kills cells by inducing ribosome biogenesis stress
- (2017) Peter M Bruno et al. NATURE MEDICINE
- Decoupling stability and release in disulfide bonds with antibody-small molecule conjugates
- (2017) Thomas H. Pillow et al. Chemical Science
- Using an RNAi Signature Assay To Guide the Design of Three-Drug-Conjugated Nanoparticles with Validated Mechanisms, In Vivo Efficacy, and Low Toxicity
- (2016) Jonathan C. Barnes et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Recent advances in the construction of antibody–drug conjugates
- (2016) Vijay Chudasama et al. Nature Chemistry
- Functional characterization of a panel of high-grade serous ovarian cancer cell lines as representative experimental models of the disease
- (2016) James Haley et al. Oncotarget
- Ovarian cancer
- (2016) Ursula A. Matulonis et al. Nature Reviews Disease Primers
- Analysis of nanoparticle delivery to tumours
- (2016) Stefan Wilhelm et al. Nature Reviews Materials
- Disulfide-Based Multifunctional Conjugates for Targeted Theranostic Drug Delivery
- (2015) Min Hee Lee et al. ACCOUNTS OF CHEMICAL RESEARCH
- A Pt(IV) Pro-drug Preferentially Targets Indoleamine-2,3-dioxygenase, Providing Enhanced Ovarian Cancer Immuno-Chemotherapy
- (2015) Samuel G. Awuah et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Principles of nanoparticle design for overcoming biological barriers to drug delivery
- (2015) Elvin Blanco et al. NATURE BIOTECHNOLOGY
- AAV9 delivering a modified human Mullerian inhibiting substance as a gene therapy in patient-derived xenografts of ovarian cancer
- (2015) David Pépin et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Latest research and treatment of advanced-stage epithelial ovarian cancer
- (2013) Robert L. Coleman et al. Nature Reviews Clinical Oncology
- Modulation of oxidative stress as an anticancer strategy
- (2013) Chiara Gorrini et al. NATURE REVIEWS DRUG DISCOVERY
- Bispecific small molecule-antibody conjugate targeting prostate cancer
- (2013) C. H. Kim et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Antibody Therapeutics in Cancer
- (2013) M. X. Sliwkowski et al. SCIENCE
- One-step synthesis of water dispersible silica nanoplates
- (2012) Hong Chen et al. CHEMICAL COMMUNICATIONS
- Biodegradable copolymers with identical cationic segments and their performance in siRNA delivery
- (2012) Ruogu Qi et al. JOURNAL OF CONTROLLED RELEASE
- Doxil® — The first FDA-approved nano-drug: Lessons learned
- (2012) Yechezkel (Chezy) Barenholz JOURNAL OF CONTROLLED RELEASE
- Defining principles of combination drug mechanisms of action
- (2012) J. R. Pritchard et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Nanoparticle Delivery of Cancer Drugs
- (2011) Andrew Z. Wang et al. Annual Review of Medicine
- Toxicological considerations when creating nanoparticle-based drugs and drug delivery systems
- (2011) Arati Sharma et al. Expert Opinion on Drug Metabolism & Toxicology
- Brentuximab Vedotin (SGN-35), an antibody–drug conjugate for the treatment of CD30-positive malignancies
- (2011) Antonio Gualberto EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Antibody–drug conjugates: targeted drug delivery for cancer
- (2010) Stephen C Alley et al. CURRENT OPINION IN CHEMICAL BIOLOGY
- A mammalian functional-genetic approach to characterizing cancer therapeutics
- (2010) Hai Jiang et al. Nature Chemical Biology
- Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas
- (2010) Anas Younes et al. NEW ENGLAND JOURNAL OF MEDICINE
- Small-molecule delivery by nanoparticles for anticancer therapy
- (2010) Zhuo (Georgia) Chen TRENDS IN MOLECULAR MEDICINE
- Small-molecule-directed nanoparticle assembly towards stimuli-responsive nanocomposites
- (2009) Yue Zhao et al. NATURE MATERIALS
- Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?
- (2009) Dunyaporn Trachootham et al. NATURE REVIEWS DRUG DISCOVERY
- Nanoparticle therapeutics: an emerging treatment modality for cancer
- (2008) Mark E. Davis et al. NATURE REVIEWS DRUG DISCOVERY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started